Diadema Partners’s Ascendis Pharma A/S ASND Stock Holding History

Diadema Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,840	Closed	-$1.46M	–	153
2025 Q4	$1.46M	Sell	6,840 -20,732	-75%	-$4.28M	0.25%	81
2025 Q3	$5.48M	Buy	+27,572	New	+$5.14M	1.4%	24
2025 Q2	–	Sell	-8,321	Closed	-$1.3M	–	101
2025 Q1	$1.3M	Sell	8,321 -16,955	-67%	-$2.42M	0.34%	57
2024 Q4	$3.48M	Buy	+25,276	New	+$3.32M	1.49%	20

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Diadema Partners's ASND Position: Q1 2026 in Review

Diadema Partners sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 6,840 shares — an estimated $1.46M sold.

Diadema Partners first reported a position in ASND in Q4 2024 and held it in 4 quarters. The position peaked at $5.48M in Q3 2025. 274 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Diadema Partners reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
Diadema Partners sold 6,840 Ascendis Pharma A/S shares in Q1 2026, an estimated $1.46M.
Diadema Partners first reported a position in Ascendis Pharma A/S in Q4 2024 and held it in 4 quarters.
Diadema Partners's Ascendis Pharma A/S position peaked at $5.48M in Q3 2025.
274 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.